Summary
Other Scenarios:
- KOSP - PG
- KOSP - JNJ
- PG - ARXT
- JNJ - ARXT
| Buyer: | KOS Pharmaceuticals, Inc. (KOSP) | Last Price: | 48.51 | Market Cap.: | 2.30B |
|---|---|---|---|---|---|
| Target: | Adams Respiratory Therapeutics, Inc. (ARXT) | Last Price: | 43.01 | Market Cap.: | 1.51B |
Lines of Business Summary:
- KOS Pharmaceuticals, Inc. (KOSP) competes in 1 industry and 32 product/service groups
- Adams Respiratory Therapeutics, Inc. (ARXT) competes in 1 industry and 5 product/service groups
- A combined entity will have 1% Product/Service Group overlap
- KOS Pharmaceuticals, Inc. (KOSP) has 0 and Adams Respiratory Therapeutics, Inc. (ARXT) has 4 customers that derive significant revenue from each. They share 0 in common.
Product Summary:
Overlap & Complementary Sectors
| Sector | Buyer | Target | # of Focused Companies |
|---|---|---|---|
*Healthcare |
|
|
872 |
Biopharmaceuticals |
|
|
329 |
|
Medical Devices |
|
246 | |
|
Outsourced Services |
|
66 |
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Sample Products in Similar Lines of Business |
Sample Products in Complementary Lines of Business |
||
Buyer (Total: 27)
|
Target (Total: 8)
|
Buyer
|
Targetn/a |
Business Relationship Summary:
Top Key Suppliers |
Top Key Customers |
||
Buyer (Total: 3)
|
Target (Total: 3)
|
Buyer (Total: 1)
|
Target (Total: 4)
|
Key Financial Summary:
Key Metrics
| Buyer | Target | |
|---|---|---|
| Number of Employees | 1,361 | 496 |
| Revenue Per Employee | 659,689.8 | 1,009,222.0 |
| Total Revenue | 223.7 | 52.8 |
| Total Expenses | 208.8 | 41.9 |
Other Revenue
|
0.0 | 0.0 |
|
Cost of Revenue
|
25.8 | 10.8 |
|
SG&A Expense
|
123.5 | 25.0 |
|
Research & Development
|
59.6 | 7.5 |
|
Other Operating Expense
|
0.0 | 0.0 |
|
Operating Income
|
14.8 | 11.0 |
|
Unusual Income
|
0.0 | 0.0 |
|
LT Debt to Capital
|
3.91 | 0 |
|
Fwd P/E
|
28.09 | 24.07 |
|
Fwd P/Rev
|
2.68 | 4.12 |
| Book Value | 738.1 | 222.3 |
|
Curr Portion of LTD/Cap Lease
|
0.1 | 0.0 |
Individual Company Summary
Focused
Buyer
Focused ():
*Healthcare > Biopharmaceuticals > Cardiovascular System
Target
Focused ():
*Healthcare > Biopharmaceuticals > Respiratory System > Upper Respiratory Tract Disorders > Coughs/Colds
Business Description
Buyer
Kos Pharmaceuticals, Inc. (Kos) is a fully integrated specialty pharmaceutical company engaged in the development and commercialization of prescription products for the treatment of chronic cardiovascular, metabolic and respiratory diseases. Kos manufactures its lead products, Niaspan and Advicor, and markets them directly through its own sales force and co-promotion partners in the United States, through its commercialization partner in Canada and through its commercialization partner and license arrangements outside of the United States, Canada and Japan.
Target
Adams Respiratory Therapeutics, Inc. is a specialty pharmaceutical company focused on late-stage development, commercialization and marketing of over-the-counter (OTC) and prescription pharmaceuticals for the treatment of respiratory disorders. The Company markets three OTC products under its Mucinex brand, one product under its Humibid brand, two products under Delsym brand and four products under Children's Mucinex line of products. In June 2006, the Company acquired the United States marketing and sales rights to Delsym from UCB, Inc. (UCB). Delsym is an OTC 12-hour liquid cough suppressant.
Deal Summary
Key Ratios
| Buyer | Target | |
|---|---|---|
|
Gross Margin %
|
87.65 | 79.36 |
|
Operating Margin %
|
12.48 | 31.85 |
|
Quick Ratio
|
2.8 | 2.84 |
|
Current Ratio
|
3.19 | 3.52 |
|
Coverage Ratio
|
0.15 | 0 |
| Total Assets | 996.0 | 252.6 |
| Return on Equity % | 9.48 | 20.85 |
| Return on Assets % | 7.02 | 18.35 |
|
Cash+ ST Inv. Per Share
|
9.78 | 1.52 |
| Total Debt | 30.1 | 0.0 |
| Total Debt to Equity % | 4.08 | 0 |
| Total Debt to Tangible Equity % | 5.77 | 0 |
|
Debt to Asset %
|
3.03 | 0.00 |
Product Summary
| Sector | Buyer | Target |
|---|---|---|
|
*Healthcare |
|
|
Biopharmaceuticals |
|
|
|
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
|
|
|
|
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
|
|
|
|
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
|
|
|
|
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
|
|
|
|
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
|
|
|
|
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes therapeutics that treat female genital disorders, pregnancy, and childbirth.
|
|
|
|
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
|
|
|
|
Weight Management
The Weight Management Subsectors includes herapeutics that treat and manage weight disorders.
|
|
|
|
Wound Management
The Wound Management Subsector includes therapeutics that treat cuts, abrasions, and burns from trauma or diseases.
|
|
|
|
Medical Devices |
|
|
|
Drug Delivery
The Drug Delivery Subsector includes medical devices that facilitate the delivery of medications through different anatomical entryways, including blood vessels, skin, the mouth, and the lungs. Common devices in this sector include vascular access catheters, needles, implants, and inhalers.
|
|
|
|
Outsourced Services |
|
|
|
Drug Delivery Technology
The Drug Delivery Technology Subsector includes companies that develop novel delivery methods for therapeutics.
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Product Details
| Sector | Buyer | Target |
|---|---|---|
|
*Healthcare |
|
|
|
Biopharmaceuticals |
|
|
Cardiovascular System |
|
|
Heart Disorders |
|
|
|
Angina |
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat chest pains by preventing the entry of calcium into heart muscle cells.
Buyer Products:
|
|
|
|
Myocardial Infarction (MI) |
|
|
|
Free Fatty Acid Inhibitors
Therapeutics that treat irreversible damage to the heart muscle by inhibiting the release of fatty acids from adipose tissue.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Vascular Disorders |
|
|
|
Atherosclerosis |
|
|
|
Free Fatty Acid Inhibitors
Therapeutics that treat the narrowing or hardening of arteries by inhibiting the release of fatty acids from adipose tissue.
Buyer Products:
|
|
|
|
Hypertension |
|
|
|
Angiotensin II Receptor Antagonists
Therapeutics that treat high blood pressure by blocking the angiotensin II receptor.
Buyer Products:
|
|
|
|
Angiotensin II Receptor Antagonists/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by blocking the angiotensin II receptor and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
|
Peripheral Vascular Disease |
|
|
|
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat arterial obstruction outside of the heart by inhibiting the release of fatty acids from adipose tissue and blocking cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Digestive System |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Endocrinology/Metabolism |
|
|
|
Intermediary Metabolism Disorders |
|
|
|
Hypercholesterolemia |
|
|
|
Free Fatty Acid Inhibitors
Therapeutics that treat the abnormally high concentrations of cholesterol by inhibiting the release of fatty acids from adipose tissue.
Buyer Products:
|
|
|
|
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat elevated cholesterol by inhibiting the release of fatty acids from adipose tissue and blocking cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Hyperlipidemia |
|
|
|
Free Fatty Acid Inhibitors
Therapeutics that inhibit the release of fatty acids from adipose tissue.
Buyer Products:
|
|
|
|
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat hyperlipidemia by inhibiting the release of free fatty acid from adipose tissues as well as blocking cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Hematology |
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Serum Factor Disorders |
|
|
|
Hypercholesterolemia |
|
|
|
Free Fatty Acid Inhibitors
Therapeutics that treat the abnormally high concentrations of cholesterol by inhibiting the release of fatty acids from adipose tissue.
Buyer Products:
|
|
|
|
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat the abnormally high concentrations of cholesterol by inhibiting the release of fatty acids from adipose tissue and blocking cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Hyperlipidemia |
|
|
|
Free Fatty Acid Inhibitors
Therapeutics that inhibit the release of fatty acids from adipose tissue.
Buyer Products:
|
|
|
|
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat hyperlipidemia by inhibiting the release of free fatty acid from adipose tissues as well as blocking cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Immunology |
|
|
|
Immune Deficiency Disorders |
|
|
|
Hereditary Angioedema |
|
|
|
Bradykinin B2 Receptor Antagonists
Therapeutics that treat swelling under the skin caused by the absence of an essential immune regulator by inhibiting the release of bradykinin, a peptide hormone which is released during trauma.
Buyer Products:
|
|
|
|
Obstetrics/Gynecology |
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of female reproductive disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Respiratory System |
|
|
|
Lower Respiratory Tract Disorders (Lung Disorders) |
|
|
|
Asthma |
|
|
|
Prophylactic Treatments |
|
|
|
Beta Adrenergic Receptor Agonists/Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat asthma by reducing inflammation in the lungs with steroids and that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Buyer Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat asthma by reducing inflammation in the lung passages with steroids.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Upper Respiratory Tract Disorders |
|
|
|
Coughs/Colds |
|
|
|
Antitussives
Therapeutics that relieve or prevent coughs.
Target Products:
|
|
|
|
Antitussives/Expectorants
Therapeutics that treat coughs and colds by suppressing coughs and helping ejection of the mucous.
Target Products:
|
|
|
|
Decongestants/Expectorants
Therapeutics that treat coughs and colds by reducing mucous build up and help in ejection of mucous.
Target Products:
|
|
|
|
Expectorants
Therapeutics that treat coughs and colds by helping in the ejection of mucous.
Target Products:
|
|
|
|
Weight Management |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of weight disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Wound Management |
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of wounds in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Medical Devices |
|
|
|
Drug Delivery |
|
|
|
Pulmonary Delivery |
|
|
|
Aerosol Therapy |
|
|
|
Metered Dose |
|
|
|
Liquid |
|
|
|
Breath Actuated (BAI)
Inhalation devices which are activated by the patients' inspiration
Buyer Products:
|
|
|
|
Outsourced Services |
|
|
|
Drug Delivery Technology |
|
|
|
Oral Delivery |
|
|
|
Polymer Coated
Drug Delivery Technologies used to deliver drugs in a polymer based matrix to hold/enclose the drug.
Buyer Products:
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Relationship Details
Key Competitors
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
Pfizer Inc.
|
|
n/a | 198,473.286 | 15.73 | 13.44 | 4.11 | 4.18 | n/a | |
|
Novartis AG (ADR)
|
|
n/a | 142,354.711 | 20.75 | 19.67 | 3.93 | 3.89 | 3.69 | |
|
Schering-Plough Corporation
|
|
n/a | 33,626.034 | 34.35 | 28.12 | 3.28 | 3.26 | 4.36 | |
| Buyer | |||||||||
|
Pfizer Inc.
|
|
n/a | 198,473.286 | 15.73 | 13.44 | 4.11 | 4.18 | n/a | |
|
GlaxoSmithKline plc (ADR)
|
|
n/a | 154,111.279 | 15.40 | 16.42 | 3.52 | 3.62 | 15.36 | |
|
Novartis AG (ADR)
|
|
n/a | 142,354.711 | 20.75 | 19.67 | 3.93 | 3.89 | 3.69 | |
|
Merck & Co., Inc.
|
|
n/a | 100,297.736 | 19.75 | 18.41 | 4.49 | 4.66 | n/a | |
|
AstraZeneca plc (ADR)
|
|
n/a | 91,746.689 | 15.72 | 16.20 | 3.58 | 3.69 | 9.20 | |
|
Abbott Laboratories
|
|
n/a | 72,830.558 | 22.98 | 19.08 | 3.27 | 3.27 | n/a | |
|
Bristol Myers Squibb Co.
|
|
n/a | 48,553.923 | 21.89 | 23.59 | 2.59 | 2.70 | n/a | |
|
Schering-Plough Corporation
|
|
n/a | 33,626.034 | 34.35 | 28.12 | 3.28 | 3.26 | 4.36 | |
|
Forest Laboratories, Inc.
|
|
n/a | 15,224.218 | 20.89 | 18.46 | 4.79 | 4.69 | n/a | |
|
Nektar Therapeutics
|
|
n/a | 1,314.334 | n/a | -10.51 | 8.30 | 7.14 | 7.46 | |
|
MannKind Corporation
|
|
n/a | 982.591 | n/a | -4.79 | 9,899.85 | 80.55 | 8.37 | |
|
Sciele Pharma Inc.
|
|
n/a | 763.228 | 17.79 | 17.82 | 2.89 | 2.53 | 12.02 | |
|
DepoMed, Inc.
|
|
n/a | 179.212 | n/a | -6.14 | 23.85 | 13.89 | n/a | |
|
Medicure Inc. (USA)
|
|
n/a | 130.746 | n/a | n/a | 160.11 | n/a | 15.27 | |
| Target | |||||||||
|
The Procter & Gamble Company
|
|
n/a | 201,811.395 | 23.64 | 21.10 | 2.96 | 2.67 | n/a | |
|
Johnson & Johnson
|
|
n/a | 199,398.736 | 18.02 | 18.45 | 3.82 | 3.78 | n/a | |
|
Pfizer Inc.
|
|
n/a | 198,473.286 | 15.73 | 13.44 | 4.11 | 4.18 | n/a | |
|
Novartis AG (ADR)
|
|
n/a | 142,354.711 | 20.75 | 19.67 | 3.93 | 3.89 | 3.69 | |
|
Wyeth
|
|
n/a | 69,974.213 | 17.18 | 16.60 | 3.52 | 3.51 | n/a | |
|
Bayer AG (ADR)
|
|
n/a | 36,750.709 | 18.09 | 16.81 | 1.03 | 1.17 | n/a | |
|
Schering-Plough Corporation
|
|
n/a | 33,626.034 | 34.35 | 28.12 | 3.28 | 3.26 | 4.36 | |
|
CVS Corporation
|
|
n/a | 25,628.336 | 19.53 | 20.49 | 0.65 | 0.60 | 5.64 | |
- Defined by the Company
- Defined by Others
Dependent Suppliers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Barr Pharmaceuticals, Inc.
|
|
n/a | 5,391.955 | 16.02 | 15.68 | 4.10 | 3.81 | 4.40 | |
|
Biovail Corporation (USA)
|
|
n/a | 2,538.085 | 6.93 | 6.93 | 2.49 | 2.46 | 6.76 | |
|
Inyx, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Target | |||||||||
|
Cardinal Health, Inc.
|
|
n/a | 26,140.058 | 26.14 | 17.82 | 0.32 | 0.30 | 7.76 | |
|
UCB S.A.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Boehringer Ingelheim GmbH
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Key Customers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Government - United States
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Target | |||||||||
|
Wal-Mart Stores, Inc.
|
|
10.00% | 211,494.994 | 19.84 | 17.91 | 0.64 | 0.62 | 4.91 | |
|
Walgreen Company
|
|
10.00% | 43,182.977 | 24.67 | 21.78 | 0.91 | 0.81 | 4.27 | |
|
CVS Corporation
|
|
10.00% | 25,628.336 | 19.53 | 20.49 | 0.65 | 0.60 | 5.64 | |
|
McKesson Corporation
|
|
10.00% | 15,236.009 | 19.94 | 18.78 | 0.17 | 0.16 | 3.83 | |
- Defined by the Company
- Defined by Others
Key Partners
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Barr Pharmaceuticals, Inc.
|
|
n/a | 5,391.955 | 16.02 | 15.68 | 4.10 | 3.81 | 4.40 | |
|
Biovail Corporation (USA)
|
|
n/a | 2,538.085 | 6.93 | 6.93 | 2.49 | 2.46 | 6.76 | |
|
SkyePharma PLC (ADR)
|
|
n/a | 354.269 | n/a | n/a | 3.73 | n/a | n/a | |
|
University of Southern California
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Strix Systems, Inc
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Boston University
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Arisaph Pharmaceuticals, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Merck KGaA
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Tufts University
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Oryx Pharmaceuticals Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Jerini AG
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Target | |||||||||
|
Wal-Mart Stores, Inc.
|
|
n/a | 211,494.994 | 19.84 | 17.91 | 0.64 | 0.62 | 4.91 | |
|
Target Corporation
|
|
n/a | 50,285.052 | 19.83 | 18.94 | 0.91 | 0.86 | 3.50 | |
|
Walgreen Company
|
|
n/a | 43,182.977 | 24.67 | 21.78 | 0.91 | 0.81 | 4.27 | |
|
Sears Holdings Corporation
|
|
n/a | 27,254.188 | 23.10 | 20.97 | 0.51 | 0.54 | 4.35 | |
|
Cardinal Health, Inc.
|
|
n/a | 26,140.058 | 26.14 | 17.82 | 0.32 | 0.30 | 7.76 | |
|
CVS Corporation
|
|
n/a | 25,628.336 | 19.53 | 20.49 | 0.65 | 0.60 | 5.64 | |
|
The Kroger Co.
|
|
n/a | 16,357.290 | 16.66 | 15.90 | 0.26 | 0.25 | 6.64 | |
|
McKesson Corporation
|
|
n/a | 15,236.009 | 19.94 | 18.78 | 0.17 | 0.16 | 3.83 | |
|
Safeway Inc.
|
|
n/a | 12,864.566 | 17.48 | 16.80 | 0.32 | 0.32 | 4.07 | |
|
AmerisourceBergen Corp.
|
|
n/a | 9,419.104 | 25.79 | 22.14 | 0.16 | 0.16 | 5.69 | |
|
Rite Aid Corporation
|
|
n/a | 2,368.368 | 1.94 | n/a | 0.14 | 0.13 | 3.06 | |
|
Albertsons LLC
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Boehringer Ingelheim GmbH
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
UCB S.A.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Financials
| Buyer | Target | Combined Entity | |
|---|---|---|---|
| Income Statement | |||
| Operating Items | |||
| Revenue | 813.5 | 239.1 | 1,052.6 |
|
Other Revenue
|
0.0 | 0.0 | 0.0 |
| Total Revenue | 813.5 | 239.1 | 1,052.6 |
|
Cost of Revenue
|
100.5 | 49.4 | 149.8 |
|
SG&A Expense
|
449.3 | 99.0 | 548.3 |
|
Depreciation & Amortization
|
0.0 | 0.0 | 0.0 |
|
Research & Development
|
162.2 | 18.9 | 181.1 |
|
Interest Expense
|
0.0 | -4.3 | -4.3 |
|
Other Operating Expense
|
0.0 | 0.0 | 0.0 |
| Total Expenses | 712.0 | 163.0 | 874.9 |
|
Operating Income
|
101.5 | 76.2 | 177.7 |
| Non Operating Items | |||
|
Interest Expense (Inc.), Net Non-Oprtng
|
14.8 | 0.0 | 14.8 |
|
Other, Net
|
-0.2 | 0.0 | -0.2 |
| Income Before Taxes | 116.1 | 76.2 | 192.3 |
| Income Taxes | 46.2 | 29.8 | 76.0 |
| Income After Taxes | 70.0 | 46.4 | 116.3 |
|
Net Income - Excl. Xord. Items
|
70.0 | 46.4 | 116.3 |
|
Net Income - Incl. Xord. Items
|
70.0 | 46.4 | 116.3 |
|
Income Avail. to Common
|
70.0 | 46.4 | 116.3 |
| Share Items | |||
|
Basic Avg. Shares Outstanding
|
47.3 | 34.8 | 82.1 |
|
Basic EPS - Excl. Xord. Items
|
1.48 | 1.33 | 1.42 |
|
Basic EPS - Incl. Xord. Items
|
1.48 | 1.33 | 1.42 |
| Full Dilution Adjustment | 0.2 | 0.0 | 0.2 |
| Fully Diluted Shares Outstanding | 49.4 | 37.5 | 86.9 |
|
F.D. EPS - Excl. Xord. Items
|
1.42 | 1.24 | 1.34 |
|
F.D. EPS - Incl. Xord. Items
|
1.42 | 1.24 | 1.34 |
| Balance Sheet | |||
| Assets | |||
|
Cash and Equivalents
|
480.1 | 34.8 | 514.9 |
|
ST Investments
|
2.7 | 22.2 | 24.9 |
|
Accounts Receivable
|
104.5 | 23.5 | 128.0 |
|
Inventory
|
25.4 | 10.6 | 36.0 |
|
Prepayments and Advances
|
16.9 | 4.9 | 21.8 |
|
Other Current Assets
|
37.9 | 3.7 | 41.6 |
|
Current Assets
|
667.4 | 99.6 | 767.1 |
|
PPE
|
0.0 | 8.1 | 8.1 |
|
Accum D&A
|
0.0 | -0.7 | -0.7 |
|
PPE, Net
|
38.0 | 7.4 | 45.4 |
| Goodwill & Intangibles | 215.4 | 127.1 | 342.5 |
| Long Term Investments | 20.8 | 0.0 | 20.8 |
| Other Assets | 0.0 | 0.0 | 0.0 |
|
Other LT Assets
|
54.4 | 18.4 | 72.8 |
| Total Assets | 996.0 | 252.6 | 1,248.6 |
| Liabilities | |||
| Accounts Payable | 23.9 | 15.2 | 39.1 |
| Payable/Accrued | 0.0 | 0.0 | 0.0 |
| Accrued Expenses | 183.7 | 11.5 | 195.2 |
|
ST Debt
|
0.0 | 0.0 | 0.0 |
|
Curr Port of LTD & Cap Lease Oblg
|
0.1 | 0.0 | 0.1 |
| Other (Current) Liabilities | 1.6 | 1.6 | 3.3 |
|
Current Liab.
|
209.4 | 28.3 | 237.7 |
|
LT Debt
|
30.0 | 0.0 | 30.0 |
|
Total LT Debt
|
30.0 | 0.0 | 30.0 |
|
Other LT Liab.
|
18.5 | 2.0 | 20.5 |
|
Total Liabilities
|
257.9 | 30.3 | 288.2 |
| Shareholders Equity | |||
| Common Stock | 0.5 | 0.3 | 0.8 |
| Additional Paid in Capital | 707.5 | 464.9 | 1,172.3 |
| Retained Earnings | 24.6 | -243.0 | -218.4 |
| Other Equity | 5.6 | 0.0 | 5.6 |
|
Total Equity
|
738.1 | 222.3 | 960.4 |
|
Total Liab. & Equity
|
996.0 | 252.6 | 1,248.6 |
|
Shares Outstanding
|
47.4 | 34.9 | 82.2 |
| Cash Flow | |||
| Operating Cash Flow | |||
| CF Net Income | 72.0 | 46.4 | 118.3 |
| CF Depreciation | 7.4 | 1.3 | 8.6 |
| CF Amortization | 29.5 | 0.0 | 29.5 |
| CF Deferred Taxes | -29.3 | 2.0 | -27.3 |
| Other Non-Cash Items | 51.8 | 6.4 | 58.1 |
| Change in Working Capital | 65.5 | -8.4 | 57.1 |
| Total Cash From Operating Activities | 196.8 | 47.6 | 244.4 |
| Investing Cash Flow (not calculated) | |||
| Capital Expenditures | -20.6 | -128.8 | -149.4 |
| Other Investing Cash Flows | -11.1 | -38.2 | -49.4 |
| Total Cash From Investing Activities | -31.8 | -167.0 | -198.8 |
| Financing Cash Flow (not calculated) | |||
| Dividends Paid | 0.0 | 0.0 | 0.0 |
| Purchase Or Sale of Stock | 39.5 | 110.5 | 150.0 |
| Purchase and Retirement of Debt | 29.9 | 0.0 | 29.9 |
| Other Financing Cash Flow | 1.7 | 19.0 | 20.8 |
| Total Cash From Financing Activities | 71.1 | 129.6 | 200.7 |
| Exchange Rate Effects | 0.0 | 0.0 | 0.0 |
| Net Change in Cash | 236.1 | 10.2 | 246.3 |
| Cash Taxes Paid | 15.3 | 10.7 | 26.0 |
| Cash Interest Paid | 0.7 | 0.0 | 0.7 |